Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05879822 |
Title评估INCB099280对免疫检查点抑制剂无效的特定实体瘤患者的作用的研究 | 阶段
第二阶段
|
Date Added 2023-05-30 |
地点
巴西
中国 格鲁吉亚 希腊 Hungary 新西兰 Romania 南非 Turkey |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
INCB099280 |
标签
MSI-H/ MMRd
|
| NCT ID NCT05865535 |
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia | 阶段
第 1 阶段
|
Date Added 2023-05-19 |
地点
California, United States
Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05838768 |
TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 阶段
第 1 阶段
|
Date Added 2023-05-03 |
地点
California, United States
Massachusetts, United States New York, United States Texas, United States 比利时 中国 法国 德国 以色列 意大利 日本 大韩民国 挪威 新加坡 西班牙 瑞典 台湾 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
HRO761, Irinotecan |
标签
MSI-H/ MMRd
|
| NCT ID NCT05799443 |
TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-04-05 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
cetuximab, Irinotecan Hydrochloride, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05798533 |
TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | 阶段
第 1 阶段
|
Date Added 2023-04-04 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Cyclophosphamide, Fludarabine, Interleukin-2 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05785325 |
TitleRC48-ADC 联合贝伐单抗治疗 HER2 阳性晚期结直肠癌 | 阶段
第二阶段
|
Date Added 2023-03-27 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
RC48-ADC 加贝伐单抗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05784688 |
TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2023-03-27 |
地点
Texas, United States
Washington, United States 大韩民国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
TU2218 + Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05783089 |
TitleMSLN-targeted CAR-T Cells in Solid Tumors. | 阶段
第 1 阶段
|
Date Added 2023-03-24 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05771181 |
TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | 阶段
第二阶段
|
Date Added 2023-03-16 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Fruquintinib, Tislelizumab, Vitamin E |
标签
MSS/ MMRp
|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | 阶段
第二阶段
|
Date Added 2023-03-15 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Atezolizumab |
标签
MSI-H/ MMRd
|
